Roche Holding AG
ROG
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
stocks
10 global stocks for a recession
These undervalued stocks come from high-quality companies in defensive sectors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,002.60 | 100.80 | -1.24% |
| CAC 40 | 8,025.24 | 83.33 | 1.05% |
| DAX 40 | 22,648.23 | 319.46 | 1.43% |
| Dow JONES (US) | 41,433.48 | 478.23 | -1.14% |
| FTSE 100 | 8,535.81 | 39.82 | 0.47% |
| HKSE | 23,600.31 | 181.83 | -0.76% |
| NASDAQ | 17,436.10 | 32.22 | -0.18% |
| Nikkei 225 | 36,819.09 | 25.98 | 0.07% |
| NZX 50 Index | 12,249.55 | 161.42 | -1.30% |
| S&P 500 | 5,572.07 | 42.49 | -0.76% |
| S&P/ASX 200 | 7,786.20 | 103.90 | -1.32% |
| SSE Composite Index | 3,371.92 | 7.90 | -0.23% |